Fluofarma cited in a Biocompare featured article “Flow Cytometry Gets a
Makeover”:
"If a cytometry system that adds imaging doesn’t suit your fancy,
Fluofarma has a high-content screening (HCS) platform that includes fully
automated flow cytometry, cell culture, and data analysis. They also offer a
proprietary line of recombinant fluorescent biosensors for use in HCS. 'The
combination of specifically engineered probes with analytical flow cytometry
dramatically broadens the application field of this detection technology,'
says Bruno Brisson, Fluofarma’s chief business officer, 'especially when image
segmentation is difficult, and when acquiring more than a few hundreds of
cells per condition is required. We have demonstrated that the use of these
instruments as the pivotal detection unit of versatile HCS detection platforms
is possible, and that it can supplant HCS by imaging in many key
applications'."
Read
more